Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 4,635 matching trials from the live ClinicalTrials.gov search.
Conditions
HIV-1 Infection, H1N1, Influenza, Flu
Interventions
FluMist, Fluvirin, Fluzone
Biological
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Months to 25 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Conditions
Internal Carotid Artery Stenosis, Cognitive Impairment
Interventions
Revascularization, Intensive Medical Management (IMM) alone
Procedure · Other
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 86 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more
Recruiting Not applicable Interventional

PARTNER 3 Trial - Aortic Valve-in-Valve

NCT03003299
Conditions
Aortic Stenosis, Aortic Stenosis, Severe
Interventions
Edwards SAPIEN 3/SAPIEN 3 Ultra THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2038
U.S. locations
50
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 43 more
Conditions
Lung Non-Small Cell Carcinoma, Thoracic Cancer
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Conditions
Primary Immunodeficiency
Interventions
Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%
Biological
Lead sponsor
Prometic Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more
Conditions
Degenerative Disc Disease
Interventions
Fortilink IBF System with TETRAfuse Technology
Device
Lead sponsor
Xtant Medical
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Sherman Oaks, California • Lone Tree, Colorado • Boca Raton, Florida + 11 more
Conditions
Urologic Diseases
Interventions
CEGSSS-Canadian Endourology Group Stent Symptom Score
Other
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Mayfield Heights, Ohio
Conditions
Colorectal Cancer
Interventions
Arm 1, Arm 2, Arm 3
Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
50 Years to 70 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Triple Negative Breast Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
Interventions
NKT3964, Paclitaxel, Doxorubicin
Drug
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
19 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
Conditions
Leukemia
Interventions
etoposide, mitoxantrone hydrochloride, valspodar
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
50
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 39 more
Conditions
ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions
Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2036
U.S. locations
1613
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more
Conditions
Cardiac Arrest
Interventions
Therapeutic Hypothermia, Therapeutic Normothermia
Procedure · Other
Lead sponsor
University of Michigan
Other
Eligibility
48 Hours to 18 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
Active, not recruiting Phase 2Phase 3 Interventional

Setrusumab vs Placebo for Osteogenesis Imperfecta

NCT05125809
Conditions
Osteogenesis Imperfecta
Interventions
Setrusumab, Placebo
Biological · Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
5 Years to 25 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 19 more
Completed Not applicable Interventional Results available

Goals of Care Conversations Study

NCT05001009
Conditions
Seriously Ill Patients, Cancer, Heart Failure, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, End-stage Renal Disease, End-stage Liver Disease, Dementia
Interventions
Clinician Implementation Strategy Stage 1: low intensity clinician training, Clinician Implementation Strategy Stage 2: high intensity clinician training, Low patient engagement, High patient engagement
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Palo Alto, California • West Los Angeles, California • Aurora, Colorado
Conditions
Soft Tissue Sarcoma
Interventions
Olaratumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
U.S. locations
55
States / cities
Glendale, Arizona • Greenbrae, California • Los Angeles, California + 46 more
Conditions
Heart Transplant, Heart Failure, Transplant; Failure, Heart
Interventions
Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)
Device
Lead sponsor
XVIVO Perfusion
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 9 more
Conditions
Cognitive Decline
Interventions
ProdromeNeuro Omega 3 Oil Nutritional Supplement
Dietary Supplement
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
35 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Phenylketonurias, PAH Deficiency
Interventions
HMI-102
Genetic
Lead sponsor
Homology Medicines, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Tampa, Florida + 10 more
Conditions
Biliary Atresia, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, Portal Hypertension, Liver Fibrosis, Cholestasis
Interventions
Liver Stiffness Measurement (LSM)
Other
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
Up to 21 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Conditions
Polycystic Kidney Disease, Adult, ADPKD
Interventions
Lixivaptan
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Rochester, Minnesota + 3 more
Conditions
Knee Osteoarthritis
Interventions
Amniotic Suspension Allograft, Placebo
Biological · Drug
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 30 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Billings, Montana + 2 more
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia
Interventions
IM JZP-458, IV JZP-458
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development

NCT01736553
Conditions
Spinal Muscular Atrophy (SMA)
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
Up to 6 Months
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
15
States / cities
Davis, California • Los Angeles, California • Aurora, Colorado + 12 more